ライフサイエンスコーパス: poly-

1 TKNs are formulated from a polymer, poly-(1,4-phenyleneacetone dimethylene thioketal), that

2 thyl)-N'-octadecylcarbodiimide) (Poly-3) and poly((15)N-(1-naphthyl)-(15)N'-octadecylcarbodiimide) (P

3 15)N NMR and IR spectra of the (15)N-labeled poly((15)N-(1-naphthyl)-N'-octadecylcarbodiimide) (Poly-

4 jugate, methoxy-poly (ethylene glycol)-block-poly (2-methyl-2-carboxyl-propylene carbonate-graft-SMAR

5 A new chelating resin, poly [2-(4-methoxyphenylamino)-2-oxoethyl methacrylate-c

6 Poly[{2,5-bis-(2-ethylhexyl)-3,6-bis-(thien-2-yl)-pyrrol

7 erve as templates to guide the deposition of poly (3,3'-dimethoxybenzidine) (PDB).

8 nanocomposite composed of conducting polymer poly (3,4-ethylenedioxythiophene) (PEDOT) doped with gra

9 graphene oxide (GO) doped conducting polymer poly (3,4-ethylenedioxythiophene) (PEDOT) was prepared t

10 osphatidylglycerol moiety with a beta-linked poly-(3-deoxy-d-manno-oct-2-ulosonic acid) (poly-Kdo) li

11 of charge transfer between electrodeposited poly-(3-hexylthiophene) films and a model redox-active m

12 The adhesive bonding of poly[(3,4-dihydroxystyrene)-co-styrene] may be the stron

13 e the simplest of these biomimetic polymers, poly[(3,4-dihydroxystyrene)-co-styrene].

14 Osmium tetroxide on poly (4-vinylpyridine) was used to wire the laccase for

15 ng of CAP with aptamer, immobilized onto the poly-(4-amino-3-hydroxynapthalene sulfonic acid) (p-AHNS

16 1,3]thiadiazole (9) and two polymer systems (poly[(4,4-bis(2-ethylhexyl)cyclopenta-[2,1-b:3,4-b']dith

17 iadiazolo[3,4-c]pyridine)-4,7-diyl] (10) and poly[(4,4-bis(2-ethylhexyl)cyclopenta-[2,1-b:3,4-b']dith

18 Examination of the widely used poly[(4,4-bis(2-ethylhexyl)cyclopenta-[2,1-b:3,4-b']dith

19 in blends of the polymer solar-cell material poly[[4,8-bis[(2-ethylhexyl)oxy]benzo[1,2-b:4,5-b']dithi

20 es are fabricated with these SHSAMs: ITO/IFL/poly[[4,8-bis[(2-ethylhexyl)oxy]benzo[1,2-b:4,5-b']dithi

21 rmation for spin-coated semiconducting PTB7 (poly[[4,8-bis[(2-ethylhexyl)oxy]benzo[1,2-b:4,5-b']dithi

22 s 10,370/muL, with a differential showing 5% polys, 5% monos, 10% lymphocytes, and 80% myeloid-appear

23 hotophysics of organic solar cells employing poly[(5,6-difluoro-2,1,3-benzothiadiazol-4,7-diyl)-alt-(

24 grown on aluminum foil (VACNT-Al foil) with poly (9,9-di-(2-ethylhexyl)-fluorenyl-2,7-diyl)-end capp

25 Poly (9-(2-diallylaminoethyl)adenine HCl-co-sulfur dioxi

26 near-infrared (NIR) dyes into the matrix of poly[(9,9-dioctylfluorene)-co-2,1,3-benzothiadiazole-co-

27 rst embedded the NIR dyes into the matrix of poly[(9,9-dioctylfluorene)-co-2,1,3-benzothiadiazole-co-

28 Poly (A) messenger RNA (mRNA) was purified from a set of

29 Star-PAP is a poly (A) polymerase (PAP) that is putatively required fo

30 Trypanosomes possess two canonical RNA poly (A) polymerases (PAPs) termed PAP1 and PAP2.

31 hed for cell components and protein binding, poly (A) RNA binding and RNA binding were enriched for m

32 HTTAS is 5' capped, poly (A) tailed and contains three exons, alternatively

33 he first study to reveal that TATA boxes and poly (A) tails are direct targets for BBR in its regulat

34 esent study demonstrates that TATA boxes and poly (A) tails are the first and second primary targets

35 higher levels of expression by targeting the poly (A) tails of mRNAs.

36 ulatory regions as well as the poly adenine (poly (A)) tail at the mRNA terminus.

37 dicate that a viral mRNA, with 5'-cap and 3'-poly (A), can activate IFN expression through an RNase L

38 pansion mutation in the coding region of the poly-(A) binding protein nuclear 1 (PABPN1) gene.

39 (NOT)," which catalyzes the removal of mRNA poly-(A) tails, the first obligatory step in mRNA decay.

40 Using public and proprietary poly-(A)(+) RNA-seq data as well as a collection of full

41 ttlebrush-like hydroxypropyl cellulose-graft-poly (acrylic acid) (HPC-g-PAA) as a template and was co

42 osite electrodes and polyvinyl alcohol (PVA)-poly (acrylic acid) (PAA) copolymer separator has been d

43 e iodine negativity, annexin positivity, and poly (adenosine 5'-diphosphate-ribose) polymerase cleava

44 oss of mitochondrial membrane potential, and poly (adenosine diphosphate-ribose) polymerase cleavage.

45 tion (HR) as measured by hypersensitivity to poly (adenosine diphosphate-ribose) polymerase inhibitio

46 8)F) fluorthanatrace (FTT) depicts activated poly (adenosine diphosphate-ribose)polymerase (PARP) exp

47 ), or high tidal volume ventilation plus the poly-(adenosine diphosphate-ribose) polymerase inhibitor

48 A phase II prospective clinical trial of the poly-(adenosine diphosphate-ribose) polymerase inhibitor

49 Poly (ADP ribose) (PAR) formation catalyzed by PAR polym

50 eracting with histone deacetylase (HDAC) and poly (ADP ribose) polymerase (PARP) to repress alpha-MHC

51 ide together with velaparib, an inhibitor of poly (ADP ribose) polymerase 1, is increased by up to 10

52 n the sensitivity of BRCA-mutated cancers to poly (ADP ribose) polymerase-1 (PARP1) inhibitors and pl

53 HR-deficient cancers are hypersensitive to Poly (ADP ribose)-polymerase (PARP) inhibitors, but can

54 include targeting the enzyme or one can use poly (ADP) ribose inhibitor to inhibit base excision rep

55 n of caspase-3, caspase-8, and caspase-9 and poly (ADP) ribosome polymerase.

56 he sensitivity of hLigI-deficient cells to a poly (ADP-ribose polymerase (PARP) inhibitor, expression

57 nt is mediated by the zinc finger domain and poly (ADP-ribose) (PAR).

58 f XRCC1 is required for selective binding to poly (ADP-ribose) at low levels of ADP-ribosylation, and

59 ssue, we have characterized the mechanism of poly (ADP-ribose) binding by XRCC1 and examined its impo

60 lly promoting stabilization of a new target, poly (ADP-ribose) glycohydrolase (PARG) mRNA, by binding

61 show that recombinant FUS binds directly to poly (ADP-ribose) in vitro, and that both GFP-tagged and

62 Poly (ADP-ribose) is synthesized at DNA single-strand br

63 Statistically significant inhibition of poly (ADP-ribose) levels was observed in tumor biopsies

64 We have previously demonstrated that poly (ADP-ribose) polymerase (PARP) 14, a member of the

65 ignaling events Bcl-2/Bcl-x(L) and caspase-3/poly (ADP-ribose) polymerase (PARP) activities were eval

66 emicals were tested for inhibitory effect of poly (ADP-ribose) polymerase (PARP) activity in vitro an

67 activation of caspase-8 and -3, cleavage of poly (ADP-Ribose) polymerase (PARP) and apoptosis.

68 Inhibitors against poly (ADP-ribose) polymerase (PARP) are promising target

69 nt and clinical evaluations of inhibitors of poly (ADP-ribose) polymerase (PARP) as novel targeting a

70 is evidenced by increased DNA fragmentation, poly (ADP-ribose) polymerase (PARP) cleavage and activat

71 ulation of mitochondria, and induce elevated poly (ADP-ribose) polymerase (PARP) cleavage and apoptos

72 Furthermore, z-LEVD-fmk completely prevented poly (ADP-ribose) polymerase (PARP) cleavage, E(2)-inhib

73 ion of apoptotic cell death and detection of poly (ADP-ribose) polymerase (PARP) cleavage.

74 ore susceptible to apoptotic stress based on poly (ADP-ribose) polymerase (PARP) cleavage.

75 Poly (ADP-ribose) polymerase (PARP) inhibition that impo

76 oded by PML-RARA) are extremely sensitive to poly (ADP-ribose) polymerase (PARP) inhibition, in part

77 Poly (ADP-ribose) polymerase (PARP) inhibitor (PARPi) ol

78 It was a first-in-human study of the poly (ADP-ribose) polymerase (PARP) inhibitor ABT-888 in

79 recent approval of olaparib (Lynparza), the poly (ADP-ribose) polymerase (PARP) inhibitor for treati

80 tudies suggested impressive potential when a poly (ADP-ribose) polymerase (PARP) inhibitor is given f

81 izes cancer cells to DNA damaging agents, to Poly (ADP-ribose) polymerase (PARP) inhibitors and cross

82 Poly (ADP-ribose) polymerase (PARP) inhibitors have emer

83 Poly (ADP-ribose) polymerase (PARP) inhibitors have emer

84 Poly (ADP-ribose) polymerase (PARP) inhibitors have show

85 Poly (ADP-ribose) polymerase (PARP) inhibitors have show

86 Poly (ADP-ribose) polymerase (PARP) inhibitors were foun

87 ates resistance to platinum chemotherapy and poly (ADP-ribose) polymerase (PARP) inhibitors.

88 ls is being targeted with platinum drugs and poly (ADP-ribose) polymerase (PARP) inhibitors.

89 y protein BIM, cleaved caspase 3 and cleaved poly (ADP-ribose) polymerase (PARP).

90 p53, cleaved caspase-3 and cleaved poly (ADP-ribose) polymerase (PARP).

91 005) concomitant with an increase in cleaved poly (ADP-ribose) polymerase 1 (P < 0.05), indicative of

92 re required for TOT-dependent recruitment of poly (ADP-ribose) polymerase 1 (PARP-1) and Topoisomeras

93 Poly (ADP-ribose) polymerase 1 (PARP-1) is a constitutiv

94 Inhibition of beta-catenin, poly (ADP-ribose) polymerase 1 (PARP1), or enhancer of z

95 langiectasia mutated (ATM), but dependent on poly (ADP-ribose) polymerase 1 (PARP1), which ADP ribosy

96 or cells are hypersensitive to inhibitors of poly (ADP-ribose) polymerase 1 (PARP1).

97 lementing protein 1, DNA polymerase beta, or poly (ADP-ribose) polymerase 1 activity, all of which fa

98 oughput screens identified multiple clinical poly (ADP-ribose) polymerase 1 and 2 (PARP1/2) inhibitor

99 factor/insulin-like growth factor receptor; poly (ADP-ribose) polymerase 1; and others.

100 Glutamine depletion increased caspase-3 and poly (ADP-ribose) polymerase activity after heat stress,

101 reatly reduced or ablated by an inhibitor of poly (ADP-ribose) polymerase activity.

102 termined by Western blot analysis of cleaved poly (ADP-ribose) polymerase and caspase 3.

103 caspase-8, and caspase-9 activation and less poly (ADP-ribose) polymerase cleavage compared with WT l

104 downregulation of glucose transporter-1 and poly (ADP-ribose) polymerase cleavage while preserving t

105 anism of cell death, involving apoptosis via poly (ADP-ribose) polymerase cleavage-independent of cas

106 pectively, and high selectivity toward other poly (ADP-ribose) polymerase enzymes.

107 a potential marker of long-term response to poly (ADP-ribose) polymerase inhibition and that restora

108 Purpose Data suggest that DNA damage by poly (ADP-ribose) polymerase inhibition and/or reduced v

109 reased sensitivity to ionizing radiation and poly (ADP-ribose) polymerase inhibition.

110 We investigated in vitro sensitivity to the poly (ADP-ribose) polymerase inhibitor olaparib (AZD2281

111 rpose Durable and long-term responses to the poly (ADP-ribose) polymerase inhibitor olaparib are obse

112 Olaparib (AZD2281), an orally active poly (ADP-ribose) polymerase inhibitor that induces synt

113 Olaparib is an oral poly (ADP-ribose) polymerase inhibitor with activity in

114 Ialpha inhibitor, L67, in combination with a poly (ADP-ribose) polymerase inhibitor.

115 Poly (ADP-ribose) polymerase inhibitors (PARPis) are cli

116 Promising novel therapeutic agents such as poly (ADP-ribose) polymerase inhibitors have increased a

117 d treatments such as antiangiogenic drugs or poly (ADP-ribose) polymerase inhibitors offer potential

118 receptor tyrosine kinase inhibitor XL184 and poly (ADP-ribose) polymerase inhibitors which are in ear

119 vic radiotherapy, or previous treatment with poly (ADP-ribose) polymerase inhibitors.

120 overexpression of caspase-3, higher cleaved poly (ADP-ribose) polymerase levels (p < 0.007), and a h

121 RK1 inhibition cooperates with inhibition of poly (ADP-ribose) polymerase signalling to inhibit growt

122 Caspase-3 was activated and poly (ADP-Ribose) polymerase was cleaved after curcumin

123 ivated protein (MAP) kinases, caspase-3, and poly (ADP-ribose) polymerase were monitored by Western b

124 creased levels of apoptotic markers, cleaved poly (ADP-ribose) polymerase, and caspase-3 and -8 (P <

125 tivation of caspase-8, caspase-9, caspase-3, poly (ADP-ribose) polymerase, and downregulation of Mcl-

126 is, and activation of caspase-3, -7, -8, -9, poly (ADP-ribose) polymerase, and lamin A/C.

127 thodologies for studying robust responses of poly (ADP-ribose) polymerase-1 (PARP-1) to DNA damage wi

128 Poly (ADP-ribose) polymerase-1 (PARP1) is a highly conse

129 ent of targeted agents such as inhibitors of poly (ADP-ribose) polymerase-1 and mTOR and immunomodula

130 Purpose To determine whether cotargeting poly (ADP-ribose) polymerase-1 plus androgen receptor is

131 of UVA laser induced damage in cells lacking poly (ADP-ribose) polymerase-1.

132 release, caspase 3 activity, and cleavage of poly (ADP-ribose) polymerase.

133 of the activation, and cleaved caspases and poly (ADP-ribose) polymerase.

134 of their breakage, and to be antagonized by poly (ADP-ribose) polymerase/RECQ1-regulated restart.

135 caspase-9 and caspase-3 and the cleavage of poly (ADP-ribose) polymerase; (5) upregulating pancreati

136 Rucaparib is an inhibitor of nuclear poly (ADP-ribose) polymerases (inhibition of PARP-1 > PA

137 ys conserved in all eukaryotic cells include poly (ADP-ribose) polymerases (PARPs), sirtuins, AMP-act

138 es of sub-nuclear PCNA foci, suggesting that poly (ADP-ribose) promotes XRCC1 recruitment both at sin

139 These data support the hypothesis that poly (ADP-ribose) synthesis promotes XRCC1 recruitment a

140 tro and functions in the same pathway as the poly (ADP-ribose)-binding protein APLF to accelerate chr

141 Use of poly (ADP-ribose)-polymerase inhibitors has shown that t

142 nction of the DLK regeneration pathway, that poly-(ADP ribosylation) inhibits axon regeneration acros

143 The development of poly-(ADP)ribose polymerase inhibitors for BRCA1-mutatio

144 rase 1 (PARP1) and the deribosylating enzyme poly-(ADP-ribose) glycohydrolase (PARG), which dynamical

145 r has been the exploitation of inhibitors of poly-(ADP-ribose) polymerase (PARP) for the treatment of

146 Poly-(ADP-ribose) polymerase (PARP) inhibitors (PARPis)

147 Bax and Bak, and processing of caspases and poly-(ADP-ribose) polymerase (PARP-gamma).

148 Recently, the enzyme poly-(ADP-ribose) polymerase 1 (PARP-1) was shown to be

149 teady state levels of two ALT NHEJ proteins, poly-(ADP-ribose) polymerase 1 (PARP1) and DNA ligase II

150 iated by the nuclear ADP-ribosylating enzyme poly-(ADP-ribose) polymerase 1 (PARP1) and the deribosyl

151 poly-(ADP-ribose) polymerase 14 (PARP14), an intracellul

152 as evidenced by increased cleaved caspase-3, poly-(ADP-ribose) polymerase, and cytochrome c release.

153 ntrols the activities of sirtuins, mono- and poly-(ADP-ribose) polymerases, and NAD nucleosidase.

154 ocation from mitochondria to the nucleus and poly-(ADP-ribose)-polymerase (PARP) activation.

155 Poly [ADP ribose] polymerase 1 (PARP-1) is proinflammato

156 Poly [ADP-ribose] polymerase 1 (PARP-1) is a highly abun

157 -1) liposomes were used to deliver a PARP-1 (poly [ADP-ribose] polymerase 1) inhibitor: AZ7379.

158 e amounts of ROS on activation and triggered poly-[ADP-ribose] polymerase-1-dependent apoptosis in ad

159 afer"-like bilayer film of polyelectrolytes (Poly (allyl amine hydrochloride/poly(sodium 4-styrene su

160 isacrylamide-diaminohexane) (ABP)-conjugated poly (amidoamine) (PAMAM) dendrimer (PAM-ABP) in hMSCs.

161 bust procedure for synthesis of generation-4 poly-(amidoamine) (PAMAM) dendrimers with a precisely co

162 In order to visualise both Poly-, and Mono-, ADP-ribosylation in vivo, we engineere

163 kely in vivo substrates are NAD(P)H and di-, poly-, and persulfide derivatives of coenzyme A, althoug

164 ermline configuration, express low-affinity, poly-, and self-reactive BCRs.

165 The poly- and autoreactive property is therefore not due to

166 emonstrate that bNAbs are significantly more poly- and autoreactive than nNAbs.

167 hat as a class, bNAbs are significantly more poly- and autoreactive than nNAbs.

168 The poly- and autoreactivity of bNAbs surely contribute to t

169 The strong association of poly- and autoreactivity with bNAbs, but not nNAbs from

170 (D)J mutation per se does not correlate with poly- and autoreactivity.

171 T-cell depletion, etc., alone does not cause poly- and autoreactivity.

172 x different liposome solutions prepared from poly- and mono-unsaturated and saturated (fluid vs gel p

173 ising a fair share of lignin coexisting with poly- and oligo-saccharides, have very low but variable

174 fCS poly- and oligosaccharides display low cytotoxicity in v

175 In conclusion, neutral poly- and oligosaccharides from H. suaveolens have a pre

176 olation, and complete structural analysis of poly- and oligosaccharides of Shigella sonnei phase II E

177 Increasing levels of poly- and perfluorinated alkyl substances (PFASs) have r

178 of atmospheric versus oceanic transport for poly- and perfluorinated alkyl substances (PFASs) reachi

179 describe here an efficient defluorination of poly- and perfluorinated aromatics under oxidative condi

180 y of consumer products that are treated with poly- and perfluoroalkyl substances (PFASs) and related

181 led fires has led to the co-contamination of poly- and perfluoroalkyl substances (PFASs) and trichlor

182 Poly- and perfluoroalkyl substances (PFASs) are a class

183 Growing evidence that certain poly- and perfluoroalkyl substances (PFASs) are associat

184 Poly- and perfluoroalkyl substances (PFASs) are persiste

185 Poly- and perfluoroalkyl substances (PFASs) have been de

186 is limited knowledge on the distribution of poly- and perfluoroalkyl substances (PFASs) in different

187 ata on predictors of gestational exposure to poly- and perfluoroalkyl substances (PFASs) in the Unite

188 recursors found in AFFF and a suite of other poly- and perfluoroalkyl substances (PFASs).

189 biodegradation in subsurface locations where poly- and perfluoroalkyl substances occur with hydrocarb

190 Polybrominated diphenyl ethers (PBDEs) and poly- and perfluoroalkylated substances (PFASs) were fou

191 y electropolymerization a conductive polymer poly-(aniline-co-3-aminobenzoic acid) (PANABA) then we i

192 lithium-ion (Li-ion) and lithium-polymer (Li-poly) batteries have recently become dominant in consume

193 ft-body armor containing the ballistic fiber poly[(benzo-[1,2-d:5,4-d']-benzoxazole-2,6-diyl)-1,4-phe

194 le (SPION), a biodegradable and pH-sensitive poly (beta-amino ester) (PBAE) copolymer, a chemotherape

195 chondrocytes via electroporation followed by poly (beta-amino esters) (PBAE) transfection.

196 of poly(l-lactide) and poly ethylene glycol/poly(-caprolactone), allowing diffusion-controlled relea

197 Poly-(CUG) binding proteins in the Muscleblind-like (MBN

198 polymeric non-viral vector Arginine-grafted poly (cystaminebisacrylamide-diaminohexane) (ABP)-conjug

199 are self-assembled from a block copolymer of poly (D, L-lactide) (PLA) and monomethoxy polyethylene g

200 ribe the generation and functionalization of poly (D,L-lactic-co-glycolic) acid (PLGA) particles to e

201 indings demonstrate that the prevascularized poly (D,L-lactide-co-epsilon-caprolactone) scaffold main

202 rized, subcutaneously implanted, retrievable poly (D,L-lactide-co-epsilon-caprolactone) scaffold.

203 Heparin-loaded biodegradable poly (D,L-lactide-co-glycolide) microparticles were prep

204 ery system, PTX was covalently conjugated to poly (D,L-lactide-co-glycolide) polymeric core by redox-

205 Poly (D,L-lactide-coglycolide) nanocapsules (NC) were us

206 using BVDV E2 and NS3 proteins formulated in poly-(D, L-lactic-co-glycolic acid) (PLGA) nanoparticles

207 The poly (dA-dT) tracts affect but do not deplete nucleosome

208 optimal production of IFN-beta triggered by poly (dA:dT) or HSV-1 requires IFNAR signaling.

209 ays, it was found that a Pluronic F68 coated poly (decanediol-phenylsuccinate-co-succinate) stimulate

210 alladium nanoparticles were in-situ grown on poly (diallyldimethylammonium chloride) functionalized b

211 f electrodeposited poly(thiophene) films (i) poly((diethyl)propylenedixoythiophene), P(Et)(2)ProDOT;

212 as studied using 5 mum tall line patterns of poly (dimethylsiloxane) (PDMS).

213 the development of a novel L-cysteine-based poly (disulfide amide) (Cys-PDSA) family for fabricating

214 oteins based on the self-healing capacity of poly (DL)-lactic-co-glycolic acid (PLGA) microspheres co

215 Poly (dl-lactide-co-glycolide) (PLGA) nanoparticles of a

216 Poly (ether urethane) (PEU; Biospan(R)) polymer films we

217 Self-healing poly (ethylene co-methacrylic acid) ionomers (EMAA) are

218 We present unexpected evidence that a poly (ethylene glycol) (PEG)-lipid conjugate enables cho

219 noparticles (NPs) made of poly (lactic acid) poly (ethylene glycol) block copolymer (PLA-PEG), and th

220 aaPEG) introducing an acetic acid terminated poly (ethylene glycol) methyl ether (aaPEG) onto the Thr

221 ted CdSe QDs rendered water-compatible using poly (ethylene glycol)-appended dihydrolipoic acid (DHLA

222 -OH, and its polymer-drug conjugate, methoxy-poly (ethylene glycol)-block-poly (2-methyl-2-carboxyl-p

223 ed ICG-NH2 to the pendant carboxyl groups of poly (ethylene glycol)-block-poly(2-methyl-2-carboxyl-pr

224 od using capture antibody immobilized porous poly (ethylene) glycol diacrylate (PEGDA) hydrogel micro

225 nalized gelatin, which can be crosslinked by poly-(ethylene glycol) diacrylate (PEGDA), was used.

226 senchymal stem cells (hMSCs) in a 3D printed poly-(ethylene glycol)-diacrylate (PEG-DA) hydrogel scaf

227 Using poly-(ethylene glycol)s of different molecular weights,

228 obtained from porcine carotid arteries with poly (ethylmethacrylate-co-diethylaminoethylacrylate) (8

229 that universally consist of highly conserved poly-(Gly-Ala) and poly-Ala domains.

230 a non-GGGGCC RNA sequence revealed that both poly-(glycine-arginine) and poly-(proline-arginine) prot

231 med to evaluate the role of IRF3 and IRF7 in poly (I-C)-induced signaling and synoviocyte gene expres

232 IRF3 rather than IRF7 regulates poly (I-C)-induced type I IFN responses in human synovio

233 and MIP1alpha gene expression in response to poly (I-C).

234 ed dendritic cells (MoDCs) were treated with poly (I: C) of TLR3 ligand and imiquimod of TLR7 ligand,

235 tion antibody were significantly enhanced in poly (I: C), imiquimod along with inactivated PRRSV grou

236 The TLR3 agonist poly (I:C) activated TLR3 pathway and inhibited tumor ce

237 n barrier repair genes, that the TLR3 ligand Poly (I:C) also induced expression and function of tight

238 Furthermore, poly (I:C) selectively induces the cleavage of 34-kDa sT

239 knockout myeloid cells are hyperreactive to Poly (I:C) stimulation, and TIPE2 knockout mice are hype

240 preparation of Saccharomyces cerevisiae, or poly (I:C) was coated on a microneedle with inactivated

241 nd TIPE2 knockout mice are hypersensitive to Poly (I:C)-induced lethality.

242 A interference experiments demonstrated that poly (I:C)-induced sTNFR1 shedding is mediated via activ

243 ing and lipolysis attenuated by TNFalpha and Poly (I:C).

244 hallenged with Pam3Cys and LPS, but not with Poly (I:C).

245 Polyinosinic-polycytidylic acid [Poly (I:C)], a dsRNA receptor ligand, activates Rac via

246 t time that polyinosinic-polycytidylic acid [poly (I:C)], a synthetic dsRNA analogue that signals via

247 ulated with polyinosinic-polycytidylic acid (poly [I-C]) after transfection with IRF3 or IRF7 small i

248 ranules made of cyanophycin [multi-L-arginyl-poly (L-aspartic acid)], which is synthesized by cyanoph

249 Novel nano-biocomposite films based on poly (lactic acid) (PLA) were prepared by incorporating

250 ntly loaded into nanoparticles (NPs) made of poly (lactic acid) poly (ethylene glycol) block copolyme

251 polymer hybrid nanoparticles (CSLPHNPs) with poly (lactic-co-glycolic acid) (PLGA) core and lipid lay

252 ChABC into lipid microtubes and NEP1-40 into poly (lactic-co-glycolic acid) (PLGA) microspheres, obvi

253 Poly (lactic-co-glycolic acid) (PLGA) supplies lactate t

254 se antimiR-21) encapsulated in biodegradable poly (lactic-co-glycolic acid) nanoparticles (PLGA-NP),

255 mbrane damage as compared to similarly sized poly (lactic-co-glycolic acid) particles.

256 Biocompatible poly (lactic-co-glycolic acid) was selected as the polym

257 Biodegradable poly (lactic-co-glycolic) acid (PLGA) microspheres, enca

258 To overcome this limitation, electrospun poly (lactic-co-glycolide) (PLGA) mats, which have excel

259 ization of a cationic amphiphilic copolymer, poly (lactide-co-glycolide)-graft-polyethylenimine (PgP)

260 n expresses sense and antisense tetrapeptide poly-(LPAC) and poly-(QAGR) RAN proteins, respectively.

261 As poly (methyl methacrylate) (PMMA) remains the main mater

262 s hybrid poly-(o-phenylene ethynylene)-block-poly-(methyl acrylate) block copolymers.

263 rane was fabricated with hybrid materials of poly (N-isopropylacrylamide), (PNIPAM) within polytetraf

264 can penetrate through the Au overlayer of a poly (N-isopropylacrylamide)-co-acrylic acid (pNIPAm-co-

265 terface by coating the Li metal surface with poly((N-2,2-dimethyl-1,3-dioxolane-4-methyl)-5-norbornen

266 biomolecules present in saliva by brushes of poly[(N-(2-hydroxypropyl) methacrylamide)-co-(carboxybet

267 g a novel biointerface architecture based on poly[(N-(2-hydroxypropyl) methacrylamide)-co-(carboxybet

268 perties of such a heavily n-dopable polymer, poly{[N,N'-bis(2-octyldodecyl)-1,4,5,8-naphthalenedicarb

269 hose of the corresponding backbone-insulated poly{[N,N'-bis(2-octyldodecyl)-1,4,5,8-naphthalenedicarb

270 arity and the charge transport properties of poly{[N,N'-bis(2-octyldodecyl)-1,4,5,8-naphthalenediimid

271 yl)thiophene)] (PTPD3T) and acceptor polymer poly{[N,N'-bis(2-octyldodecyl)naphthalene-1,4,5,8-bis(di

272 d electron transporting conjugated polymers, poly{[N,N9-bis(2-octyldodecyl)-naphthalene-1,4,5,8-bis(d

273 -transfer processes, giving access to linear poly-(o-phenylene ethynylene) with narrow molecular weig

274 ollowed by RAFT polymerization yields hybrid poly-(o-phenylene ethynylene)-block-poly-(methyl acrylat

275 Infrequent poly- or autoreactivity among nNAbs implies that their d

276 Abs) has been performed to determine whether poly- or autoreactivity in bNAbs is a consequence of chr

277 ed proliferative signals or exhibit enhanced poly- or autoreactivity.

278 (2)-BH(2)-NHMe-BH(3) led to the formation of poly- or oligoaminoboranes [MeNH-BH(2)](x) (x = 3 to >10

279 The flexible polymeric materials, poly (p-xylylene) (Parylene) and polyethylene naphtholat

280 Poly (polyethylene glycol citrate-co-N-isopropylacrylami

281 vealed that both poly-(glycine-arginine) and poly-(proline-arginine) proteins caused neurodegeneratio

282 s used to synthesize an ABC triblock polymer poly[(propylenesulfide)-block-(N,N-dimethylacrylamide)-b

283 y all [PSI+] prion variants require inositol poly-/pyrophosphates for their propagation, and at least

284 this study, we report on the combination of poly [pyrrole-co-3-carboxyl-pyrrole] copolymer and aptam

285 eraction on the intrinsic conjugation of the poly [pyrrole-co-3-carboxyl-pyrrole] copolymer and subse

286 e and antisense tetrapeptide poly-(LPAC) and poly-(QAGR) RAN proteins, respectively.

287 se that degrades the carbon storage molecule poly((R)-3-hydroxybutyrate) (PHB).

288 ophycin with an emphasis on the synthesis of poly[(R)-3-hydroxybutyrate] (PHB), a renewable biodegrad

289 tralizing Ab (bnAb) 2F5 has been shown to be poly-/self-reactive in vitro, and we previously demonstr

290 ucture ensemble of the tandem di-domain of a poly (U) binding protein.

291 ucleobase bias with a preference for binding poly (U) or d(T) while d(A) polymers bind with low affin

292 Notably, both saturated and (poly-)unsaturated FFAs are detected sensitively in the p

293 d (PLGA) microspheres, encapsulated within a poly (vinyl alcohol) (PVA) hydrogel matrix, present a mo

294 cost magnetic multi-walled carbon nanotubes-poly (vinyl alcohol) cryogel-micro-solid phase extractio

295 at husks were used to produce hydrogels with poly (vinyl alcohol).

296 layer was created by casting a thin layer of poly (vinyl chloride) (PVC)/nano-MIP composite on a grap

297 iple bond and an azide group on the modified poly (vinyl chloride) group of the membrane.

298 ed by modifying its counter electrode with a poly (vinylidene fluoride)/ZnO nanowire array composite.

299 of a relaxor ferroelectric terpolymer, i.e., poly (vinylidene fluoride-trifluoroethylene-chlorofluoro

300 VI] and [Os(4,4'-dimethoxy-2,2'-bipyridine)2(poly-(vinylimidazole))10Cl](+) [Os(dmobpy)PVI].